CY1124328T1 - Δραστικος και αποτελεσματικος ελεγχος tων φωσφορικων ορου για τον βελτιστο σχηματισμο των οστων - Google Patents

Δραστικος και αποτελεσματικος ελεγχος tων φωσφορικων ορου για τον βελτιστο σχηματισμο των οστων

Info

Publication number
CY1124328T1
CY1124328T1 CY20211100154T CY211100154T CY1124328T1 CY 1124328 T1 CY1124328 T1 CY 1124328T1 CY 20211100154 T CY20211100154 T CY 20211100154T CY 211100154 T CY211100154 T CY 211100154T CY 1124328 T1 CY1124328 T1 CY 1124328T1
Authority
CY
Cyprus
Prior art keywords
active
bone formation
effective control
optimal bone
phosphorus serum
Prior art date
Application number
CY20211100154T
Other languages
English (en)
Inventor
Emil Kakkis
Javier SAN MARTIN
Tomohiro Sudo
Original Assignee
Ultragenyx Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc. filed Critical Ultragenyx Pharmaceutical Inc.
Publication of CY1124328T1 publication Critical patent/CY1124328T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001132—Fibroblast growth factors [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει συνθέσεις και μεθόδους για τη θεραπευτική αντιμετώπιση μιας υποφωσφαταιμικής διαταραχής, όπως η Χ-φυλοσύνδετη υποφωσφαταιμία (XLH). Η μέθοδος ενέχει τη χορήγηση σε ένα υποκείμενο μιας φαρμακευτικής σύνθεσης η οποία περιέχει έναν προσδέτη έναντι του FGF23, όπου το δοσολογικό σχήμα του φαρμακευτικού είναι σχεδιασμένο ούτως ώστε να επιτυγχάνει δραστικό και αποτελεσματικό έλεγχο της δραστικότητας του FGF23.
CY20211100154T 2014-06-09 2021-02-23 Δραστικος και αποτελεσματικος ελεγχος tων φωσφορικων ορου για τον βελτιστο σχηματισμο των οστων CY1124328T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462009474P 2014-06-09 2014-06-09
PCT/US2015/033226 WO2015191312A1 (en) 2014-06-09 2015-05-29 The effective and efficient control of serum phosphate for optimal bone formation

Publications (1)

Publication Number Publication Date
CY1124328T1 true CY1124328T1 (el) 2022-07-22

Family

ID=54769049

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100154T CY1124328T1 (el) 2014-06-09 2021-02-23 Δραστικος και αποτελεσματικος ελεγχος tων φωσφορικων ορου για τον βελτιστο σχηματισμο των οστων

Country Status (23)

Country Link
US (4) US10639360B2 (el)
EP (2) EP3151859B1 (el)
JP (2) JP6808493B2 (el)
KR (2) KR20170013993A (el)
CN (1) CN106604743A (el)
AR (1) AR100689A1 (el)
AU (1) AU2015275128C1 (el)
BR (2) BR122023023102A2 (el)
CA (1) CA2949234C (el)
CL (1) CL2016003179A1 (el)
CY (1) CY1124328T1 (el)
DK (1) DK3151859T3 (el)
ES (1) ES2851674T3 (el)
HR (1) HRP20210250T1 (el)
HU (1) HUE053271T2 (el)
LT (1) LT3151859T (el)
MX (2) MX2016016296A (el)
PE (1) PE20170248A1 (el)
PL (1) PL3151859T3 (el)
PT (1) PT3151859T (el)
RS (1) RS61443B1 (el)
SI (1) SI3151859T1 (el)
WO (1) WO2015191312A1 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005235635B2 (en) 2004-04-21 2010-11-18 Alexion Pharmaceuticals, Inc. Bone delivery conjugates and method of using same to target proteins to bone
ES2851674T3 (es) 2014-06-09 2021-09-08 Ultragenyx Pharmaceutical Inc Control efectivo y eficaz de fosfato sérico para una formación ósea óptima
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
US11352612B2 (en) 2015-08-17 2022-06-07 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436020A4 (en) * 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
JP2019513711A (ja) 2016-04-01 2019-05-30 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
CN106709662B (zh) * 2016-12-30 2021-07-02 山东鲁能软件技术有限公司 一种电力设备运行工况划分方法
AU2018243320A1 (en) 2017-03-31 2019-10-10 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (HPP) in adults and adolescents
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
AU2005202100A1 (en) 1999-05-11 2005-06-09 Ortho-Mcneil Pharmaceutical, Inc. Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
EP1303536B1 (en) 2000-07-19 2010-03-17 Advanced Research And Technology Institute, Inc. Novel fibroblast growth factor (fgf23) and methods for use
CN101275136A (zh) 2000-08-11 2008-10-01 麒麟医药株式会社 调节磷酸代谢,钙代谢,钙化和维生素d代谢的多肽及其编码dna
AU3942202A (en) 2000-11-30 2002-06-11 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
ES2331414T3 (es) * 2001-12-28 2010-01-04 Kyowa Hakko Kirin Co Ltd Anticuerpos contra el factor 23 de crecimiento de fibroblastos.
US8158725B2 (en) 2005-08-22 2012-04-17 Bridgestone Corporation Functionalized polymers and tires therefrom
US7883705B2 (en) * 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
WO2012050673A1 (en) 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
ES2851674T3 (es) 2014-06-09 2021-09-08 Ultragenyx Pharmaceutical Inc Control efectivo y eficaz de fosfato sérico para una formación ósea óptima

Also Published As

Publication number Publication date
MX2016016296A (es) 2017-10-12
US20220133871A1 (en) 2022-05-05
EP3151859A4 (en) 2018-01-17
JP6993490B2 (ja) 2022-02-03
CL2016003179A1 (es) 2017-11-03
US11202822B2 (en) 2021-12-21
CN106604743A (zh) 2017-04-26
US10639360B2 (en) 2020-05-05
PL3151859T3 (pl) 2021-07-26
EP3151859A1 (en) 2017-04-12
US20240115683A1 (en) 2024-04-11
JP2021050226A (ja) 2021-04-01
AU2015275128B2 (en) 2019-10-31
EP3151859B1 (en) 2020-11-25
KR20210099180A (ko) 2021-08-11
CA2949234C (en) 2022-03-22
CA2949234A1 (en) 2015-12-17
RS61443B1 (sr) 2021-03-31
US11771748B2 (en) 2023-10-03
AU2015275128C1 (en) 2020-02-13
US20150353633A1 (en) 2015-12-10
KR20170013993A (ko) 2017-02-07
EP3845245A1 (en) 2021-07-07
ES2851674T3 (es) 2021-09-08
US20200330575A1 (en) 2020-10-22
LT3151859T (lt) 2021-03-25
HUE053271T2 (hu) 2021-06-28
BR122023023102A2 (pt) 2024-03-05
BR112016028567A2 (pt) 2018-01-30
PT3151859T (pt) 2021-02-03
PE20170248A1 (es) 2017-04-14
HRP20210250T1 (hr) 2021-04-02
JP2017524656A (ja) 2017-08-31
DK3151859T3 (da) 2021-02-15
SI3151859T1 (sl) 2021-06-30
WO2015191312A1 (en) 2015-12-17
AR100689A1 (es) 2016-10-26
AU2015275128A1 (en) 2016-12-08
JP6808493B2 (ja) 2021-01-06
MX2021003740A (es) 2021-05-27

Similar Documents

Publication Publication Date Title
CY1124328T1 (el) Δραστικος και αποτελεσματικος ελεγχος tων φωσφορικων ορου για τον βελτιστο σχηματισμο των οστων
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
EA201791018A1 (ru) Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
BR112017021021A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
EA201890630A1 (ru) Антитела против pd-1 и способы их применения
EA201690306A1 (ru) Ингибиторы ido
EA201591599A1 (ru) Ингибиторы ido
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
ECSP17003553A (es) Compuestos de heteroarilo para la inhibición de cinasa
EA201690152A1 (ru) Ингибиторы ido
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201591823A1 (ru) Ингибиторы ido
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
BR112015032595A8 (pt) inibidores de ido
EA201891251A1 (ru) Бициклические ингибиторы pad4
BR122020024446B8 (pt) Compostos para modulação da expressão do receptor do hormônio de crescimento
BR112016027881A2 (pt) antagonistas de pdl-1 e pd-1 para o tratamento de cânceres negativos para o hpv
BR112015023203A8 (pt) métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer.
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
EA201791259A1 (ru) Производные пиперидина в качестве ингибиторов hdac1/2
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201792580A1 (ru) Ингибиторы ido
BR112017021194A2 (pt) compostos espirocíclicos
EA201790773A1 (ru) Композиции и способы для ингибирования биологической активности растворимых биомолекул
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний